Table 6.
Self-reported ESAVIs after the first dose of any of the available vaccines.
| AstraZeneca | Pfizer/BioNTech | Sinovac | p Value * | ||||
|---|---|---|---|---|---|---|---|
| Symptoms | (n) | (%) | (n) | (%) | (n) | (%) | |
| Tachycardia | 97 | 0.6% | 40 | 0.5% | 39 | 0.7% | <0.001 |
| Diarrhea | 147 | 1.0% | 62 | 0.8% | 87 | 1.5% | <0.001 |
| Joint Pain | 862 | 5.7% | 216 | 2.6% | 109 | 1.9% | <0.001 |
| Headache | 1372 | 9.1% | 627 | 7.7% | 571 | 9.7% | <0.001 |
| Muscle Pain | 1338 | 8.9% | 507 | 6.2% | 298 | 5.1% | <0.001 |
| Pain Or Swelling at The Injection Site | 1273 | 8.5% | 1348 | 16.5% | 665 | 11.3% | <0.001 |
| Skin Rash | 56 | 0.4% | 38 | 0.5% | 25 | 0.4% | 0.002 |
| Shaking chills | 1236 | 8.2% | 250 | 3.1% | 173 | 2.9% | <0.001 |
| Fatigue Or Tiredness | 1266 | 8.4% | 620 | 7.6% | 575 | 9.8% | <0.001 |
| Mild/low grade fever (37.1–38 °C) | 857 | 5.7% | 194 | 2.4% | 75 | 1.3% | <0.001 |
| Fever (>38 °C) | 525 | 3.5% | 88 | 1.1% | 41 | 0.7% | <0.001 |
| Guillain Barre sd. | 4 | 0.0% | 3 | 0.0% | 0 | 0.0% | 0.705 |
| Facial Swelling | 9 | 0.1% | 8 | 0.1% | 3 | 0.1% | 0.212 |
| High Blood Pressure | 25 | 0.2% | 23 | 0.3% | 7 | 0.1% | 0.004 |
| Swollen Glands | 115 | 0.8% | 105 | 1.3% | 59 | 1.0% | <0.001 |
| General Discomfort | 1297 | 8.6% | 427 | 5.2% | 305 | 5.2% | <0.001 |
| Transverse Myelitis | 1 | 0.0% | 1 | 0.0% | 0 | 0.0% | 1 |
| Gastrointestinal Discomfort | 231 | 1.5% | 81 | 1.0% | 101 | 1.7% | <0.001 |
| Urinary Discomfort | 58 | 0.4% | 13 | 0.2% | 11 | 0.2% | <0.001 |
| Nausea | 317 | 2.1% | 116 | 1.4% | 133 | 2.3% | <0.001 |
| Facial Paralysis | 2 | 0.0% | 1 | 0.0% | 3 | 0.1% | 0.606 |
| Pruritus (Itching) | 109 | 0.7% | 74 | 0.9% | 54 | 0.9% | <0.001 |
| Coagulation Disorders | 14 | 0.1% | 4 | 0.0% | 2 | 0.0% | 0.002 |
| Vomit | 56 | 0.4% | 20 | 0.2% | 24 | 0.4% | <0.001 |
| Anaphylaxis | 2 | 0.0% | 2 | 0.0% | 4 | 0.1% | 0.607 |
| Total | 11,269 | 100% | 4868 | 100% | 3364 | 100% | |
* The p-value was obtained by Chi-Square test.